Matthew Zirwas, MD

In the final episode of the series, the discussion turns to therapies currently in development for CSU.

In this episode titled “Building Therapeutic Alliance and Addressing Access Barriers in CSU,” the panel focuses on practical strategies for empowering both patients and clinicians earlier in the CSU care journey.

5 dermatology takeaways from Maui Derm NP+PA Summer 2026, covering eczematous dermatitis, rosacea, blistering disease, hair loss, and pigmentation disorders.

This episode titled “Evaluating Biologic Options and Monitoring Response in CSU,” focuses on outcomes data for the biologic targeting the IL-4 receptor pathway, dupilumab.

With three advanced therapy classes now available, this episode focuses on the clinical trial evidence and safety profile supporting the oral BTK inhibitor option.

In this SDPA interview, Matthew Zirwas, MD, highlights key takeaways from his session 'Clinical Pearls for Optimizing Dermatologic Care.'

In this SDPA Conference interview, Zirwas continues his discussion of increasing environmental impacts on rates of atopic dermatitis.

Matthew Zirwas, MD, speaks in this SDPA interview about evidence for atopic dermatitis being more of an environmental disease than a genetic one.

In this episode titled “Mechanisms of Action Behind Advanced CSU Therapies,” the panel dives into the underlying immunology of CSU and how each advanced therapy class intervenes in the disease pathway.

This episode titled “Updated Guidelines and the Current CSU Treatment Landscape,” reviews the recently updated international CSU treatment guideline and how it has changed clinical practice.

In this episode titled “The Role of Dermatologists and APPs in Diagnosing CSU,” the moderator and panelist turn to the formal workup for inducible urticaria and the broader question of who should be diagnosing CSU.

This episode titled “A Practical Diagnostic Workup for CSU,” covers the practical approach to evaluating patients with recurrent hives.

At Maui Derm NP+PA Summer 2026, Matthew Zirwas, MD, shares cases of a factory worker with PPD allergy and a chronic spontaneous urticaria patient with persistent facial dermatitis.

Matthew Zirwas, MD, on why adult-onset atopic dermatitis is the most undertreated condition in dermatology and how diagnostic criteria are driving years of delayed care.

Matthew Zirwas, MD, explains why topical JAK inhibitors represent a clinical turning point for hand eczema.

Matthew Zirwas, MD, on using dupilumab and lebrikizumab to guide patch testing decisions and the 2 most missed allergens in eczematous disease.

In this episode titled “Distinguishing CSU From Chronic Inducible Urticaria Subtypes,” the panel looks at how CSU differs from chronic inducible urticaria (CIndU) and its subtypes. The panelist explains that inducible urticarias have an identifiable physical trigger, the most common being dermatographism, in which scratching, tight clothing, or waistbands provoke hives at the site of pressure. Cold-induced urticaria is another recognizable subtype, often described by patients as hives that appear after re-warming following cold exposure, such as a child breaking out after a chilly soccer practice.

Welcome back to another HCPLive Peers & Perspectives series. In this episode titled “Diagnosing the Hallmark Signs and Symptoms of CSU,” moderator Andrea Nguyen, DMSc, MPAS, PA-C, discusses chronic spontaneous urticaria (CSU) with Matthew Zirwas, MD. The episode opens with the moderator asking the panelist to describe the hallmark signs of CSU and the patient population most affected. The panelist explains that CSU is defined by spontaneously appearing hives that present as raised, red wheals surrounded by a blanched halo, can occur anywhere on the body, and typically resolve and recur unpredictably. He notes that roughly one-third of patients also develop angioedema, deep tissue swelling that commonly affects the lips, face, or hands. While CSU can occur at any age, including in children and older adults, onset is most common among women in their 20s and 30s.

This video feature highlights the views of dermatologists on prior authorization, step therapy, and issues related to these processes.

In this SDPA Summer Dermatology Meeting interview, Zirwas speaks on treatment gaps for dermatologic conditions and off-label alternatives.

Zirwas shares top dermatology studies, highlights AD misdiagnosis, and reveals how pollution and fabrics may trigger adult-onset atopic dermatitis.

Zirwas outlines a 4-visit approach to diagnosing spongiotic dermatitis, helping dermatologists manage uncertain rashes more effectively.

Experts in dermatology share practice pearls and takeaways for treatment of atopic dermatitis.

Expert dermatologists discuss treatment discontinuation as a barrier to achieving desired outcomes in atopic dermatitis.

Aaron S. Farberg, MD, comments on use of different treatments for atopic dermatitis when a patient does not respond to treatment.

Expert dermatologists review the positive impact dupilumab has on quality of life for a patient with atopic dermatitis.

Experts in dermatology discuss efficacy and patient-reported outcomes of topical and systemic JAK inhibitors and dosing guidelines in atopic dermatitis.

Matthew Zirwas, MD, provides insight into the ideal candidates for use of ruxolitinib to treat atopic dermatitis, focusing on patients with sensitive skin.

Expert dermatologists review the safety data of topical ruxolitinib in the treatment of atopic dermatitis.

Alexandra Golant, MD, highlights the positive clinical data of ruxolitinib, a topical JAK inhibitor used for the treatment of atopic dermatitis.